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Results Five patients were ultimately enroled in this 
proof-of-concept trial. All outcome measures demonstrated 
marked improvement from baseline to final follow-up: The 
mean weight bearing VAS pain score improved by 49 %, 
and the mean AOS functional score improved by 28 %. 
Bone healing was seen on CT, and reduction in oedema 
signal was seen on MRI.
Conclusion This new procedure may offer a promising 
alternative for the treatment of osteochondral defects. Fur-
ther high-quality studies are needed to confirm these results 
and to analyse the long-term effects of the procedure. The 
clinical relevance of this study is that the procedure may 
provide a less invasive option with improved bone healing 
compared to standard techniques.
Level of evidence IV.
Keywords Osteochondral defect · OCD · Osteochondritis 
dissecans · Platelet-derived growth factor · PDGF · Bone 
regeneration · Arthroscopic debridement
Introduction
The initial surgical treatment for osteochondral defect 
(OCD) of the talus is usually arthroscopic debridement via 
curettage. However, many patients do not achieve adequate 
pain relief or restoration of mobility with debridement 
alone [34, 36]. In addition, even among those patients for 
whom debridement appears to be effective, symptoms often 
recur over time.
For these patients, standard treatments include osteo-
articular autograft (or allograft) transfer (OATS) [18, 19], 
or autologous chondrocyte implantation (ACI) [2, 3, 14, 
17, 25]. These open procedures are more invasive and 
often more expensive than arthroscopy and can result in 
Abstract 
Purpose An arthroscopic procedure for the treatment of 
osteochondral defects using platelet-derived growth factor 
(PDGF) carried out in a matrix of tricalcium phosphate was 
developed. This prospective, case-series-based study was 
designed to evaluate the safety and clinical utility of this 
procedure.
Methods Patients with an isolated osteochondral defect 
larger than 5 mm long, 3 mm wide, and 5 mm deep and 
smaller than 30 mm long, 25 mm wide, or 20 mm deep 
were considered for enrolment. Only patients with chronic 
lesions were enroled. Arthroscopic debridement was fol-
lowed by the placement of recombinant human PDGF in 
a matrix of tricalcium phosphate. The Ankle Osteoarthri-
tis Scale (AOS), visual analogue scale (VAS) for pain, and 
SF-36 questionnaires were administered at 0, 2, 6, 12, and 
24 weeks. Magnetic resonance imaging (MRI) and com-
puted tomography (CT) scans were taken before and after 
surgery.
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considerable morbidity. In addition, debridement does not 
repair the underlying bone defect [15] and may thus allow 
continued progression of the lesion [36].
Researchers have sought treatment alternatives for OCD 
that could stabilise the interior of the lesion and prevent 
further collapse [1, 2, 7]. This report introduces a new 
arthroscopic procedure in which a volume-filling, osteo-
conductive material containing a diffusible growth factor 
is inserted into the OCD lesion to stimulate repair of the 
patient’s own subchondral bone. This growth factor, recom-
binant human platelet-derived growth factor (rhPDGF), has 
been found to promote healing; regeneration; and repair of 
bone, ligament, periodontal cementum, and other tissues 
[9, 22–24, 26–33, 35].
In this new procedure, arthroscopic debridement to sta-
ble, viable bone is followed by arthroscopic placement of 
rhPDGF mixed with an osteoconductive matrix of beta-tri-
calcium phosphate (β-TCP). The defect is then sealed with 
fibrin glue, and the patient is kept non-weight bearing for 
6 weeks prior to being remobilised.
The primary objective of this case-series-based study 
was to evaluate the initial safety, efficacy, and clinical util-
ity of rhPDGF/β-TCP as an arthroscopic treatment follow-
ing debridement for OCD of the talus, over the course of 
an initial 6-month follow-up. The hypothesis was that the 
procedure would result in improved pain and functional 
scores for patients with and OCD. The clinical relevance of 
this study is that, if successful, the procedure could provide 
a less invasive option with improved healing compared to 
standard techniques.
Materials and methods
This single-site, single-surgeon, prospective study, con-
ducted with enrolment from February 2012 until November 
2012, was designed as a case-series-based clinical study.
Patients diagnosed with a talar OCD were recruited for 
the study from the clinical practice of the authors. Inclu-
sion criteria included signed REB-approved informed con-
sent form (ICF) prior to enrolment; diagnosis of an iso-
lated OCD larger than 5 mm long, 3 mm wide, and 5 mm 
deep, confirmed by MRI; independent, ambulatory and 
can comply with all post-operative evaluations and visits; 
≥21 years of age or older; skeletally mature; stable ankle 
joint on history and similar ligament stability with the 
opposite ankle; <15° of hindfoot valgus and 5° of hindfoot 
varus; OCD is chronic and not secondary to acute trauma 
within the previous 6 months; if history of fracture, no 
residual deformity of the tibia, fibula, or syndesmosis; no 
prior fusions of the hindfoot (subtalar and talonavicular 
joints); body mass index (BMI) ≤35; American Society of 
Anesthesiologists (ASA) physical status classification of 
1 or 2; and has exhausted non-operative treatment. Exclu-
sion criteria included >15° of hindfoot valgus or 5° of hind-
foot varus; defect >30 mm length, 25 mm width, or 20 mm 
depth in size on MRI assessment; allergy to yeast-derived 
products; has metallic or electronically, magnetically, or 
mechanically activated implants that would contraindicate 
MRI scans of the foot; history of malignancy anywhere in 
the body; physically or mentally compromised and unable 
or unlikely to remain compliant to follow-up; history of 
drug/alcohol abuse within the 12 months prior to screening 
for study entry; pregnant, or able to become pregnant but 
not practicing a medically accepted form of birth control; 
current acute infection in area surrounding surgical site; 
history of anaphylaxis; condition is bilateral and surgery is 
to be scheduled over the course of the study; requires con-
comitant osteotomy of tibia, fibula, or calcaneus for hind-
foot deformity, or requires concomitant hindfoot fusion 
for hindfoot arthritis or deformity; undergoing any con-
comitant surgery that may invalidate outcome scores for 
this study; OCD of the tibia in isolation or in combination 
with the talar lesion; nicotine addiction or using medication 
or substances containing nicotine; cocaine abuse or use of 
cocaine derivatives; undergoing revision debridement of an 
OCD.
Data collection
Diagnosis of OCD was confirmed via baseline magnetic 
resonance imaging (MRI) scans of the lesion site prior 
to enrolment. Location and size of defect (width, depth, 
and length), were determined via ankle arthroscopy and 
recorded prior to treatment. Photographs of defect before 
and after debridement as well as any associated pathology 
(osteophytes, synovitis) were also obtained.
Patient demographics, comorbidities, and diagnoses 
were recorded preoperatively. Patient assessments were 
completed preoperatively and at 2, 6, 12, and 24 weeks 
post-operatively. Clinical outcomes were recorded preop-
eratively and at each follow-up visit using the visual ana-
logue scale (VAS) for pain [21], the Ankle Osteoarthritis 
Scale (AOS) [11], the short-form-36 (SF-36) Health Survey 
[6], and AP and lateral X-rays. All adverse events affect-
ing the ankles were also recorded at each study visit (see 
“Appendix”).
Follow-up MRI was conducted at 12 and 24 weeks, in 
order to evaluate bone marrow oedema. In addition, CT scans 
at 2 and 24 weeks were compared in order to determine heal-
ing status at the base of the OCD and fill of the graft. All scans 
were measured using InteleViewer software tools (Intelerad, 
Calgary, AB, Canada), which enable automated, quantitative 
segmentation and calculation of two-dimensional area and 
three-dimensional volume measurements (with read-outs in 
1-mm increments), as well as image registration for pre- and 
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post-treatment comparisons of patient lesions. The MRI scans 
were evaluated with sagittal and coronal sequences cut with 
the greatest amount of oedema (T2-weighted signal on fat 
suppressed images) being measured for square surface area 
of involvement. The oedema signal was measured preopera-
tively and at each follow-up period. The total area in square 
millimetres was analysed using the analysis of variance. The 
CT scan was evaluated for size of defect preoperatively and 
for fill with bone graft at both time periods. The CT was 
measured on one 0.6-mm slice on the sagittal view and one 
0.6-mm slice on the coronal view.
Surgical techniques
All procedures were performed by a single surgeon having 
advanced skills in arthroscopy and foot and ankle surgery. 
Patients were treated with arthroscopic debridement of the 
OCD to stable, viable bone via abrasive osteochondro-
plasty without microfracture or drilling. (Microfracture was 
not used because the subchondral bone was breached and 
softened in all cases). Debridement was followed by arthro-
scopic placement of a preparation containing rhPDGF and 
β-TCP (see below).
Routine ankle arthroscopy was performed using ante-
rior medial, anterior lateral, and medial portals to access 
and debride the joint. An Augment Bone Graft preparation 
(BioMimetic Inc., Memphis, TN) containing β-TCP and 
rhPDGF was then prepared using standard techniques and 
placed into the joint via the arthroscopic portal. Following 
mixing, the final consistency of the graft material is simi-
lar to that of granular wet sand. When placed near a viable 
host bone, it acts as scaffold for new bone growth; it sub-
sequently undergoes remodelling and is finally replaced by 
host bone [8]. All materials used in the components have 
been previously approved by Health Canada for the treat-
ment of foot and ankle fusion procedures and by the FDA 
for the treatment of periodontal bone defects.
Fibrin glue was then placed over the defect to ensure 
containment of TCP granules. The foot was dorsiflexed 
while the fibrin glue set, then the ankle kept dorsi-
flexed until the wounds were closed and the limb placed 
in a below-the-knee slab in dorsiflexion for 2 weeks 
post-surgery.
If all appeared stable at 2 weeks, subjects began joint 
range-of-motion exercises in a walker boot and remained 
non-weight bearing until the 6-week follow-up visit.
Outcome measures
The primary outcome measures were the VAS for pain and 
the Ankle Osteoarthritis Scale (AOS). The VAS for pain 
is a unidimensional, self-reported measure of pain inten-
sity [16, 20, 21], which has been widely used in diverse 
adult populations, including those with rheumatic disease 
[12, 13]. The AOS is a reliable, validated, patient-reported, 
ankle-specific functional outcome instrument [11]. Both 
the pain and disability components were used to calculate 
the total AOS score. (The score ranges from 0 to 100, with 
a lower score indicating more normal function). Secondary 
outcome measures included the physical component sum-
mary (PCS) and mental component summary (MCS) sub-
scales of the SF-36 Health Survey questionnaire, and MRI 
and CT scans of the affected ankles. The SF-36 is a generic, 
patient-reported measure of general health status [4, 6] that 
has been shown to have acceptable criterion validity in 
patients with end-stage ankle arthritis [20].
This study was approved by the Institutional Review 
Board of the Providence Health Care Research Institute 
at the University of British Columbia (REB #H03-50062) 
and was therefore performed in accordance with the ethi-
cal standards laid down in the 1964 Declaration of Helsinki 
and its later amendments. All patients provided informed 
consent for study enrolment and for the surgical procedure 
prior to questionnaire administration.
Table 1  Dimensions of OCD lesions from arthroscopic assessment
a Surface area was calculated as an ellipse
b Volume was calculated as a hemi-ellipsoid
Average Standard deviation
Length (mm) 14 3
Width (mm) 9 2
Depth (mm) 11 2
Surface areaa (mm2) 103 37
Volumeb (mm3) 285 139
Table 2  Mean outcome scores, pain, and disability
VAS visual analogue scale, AOS Ankle Osteoarthritis Scale, SF-36 short-form (36) Health Survey, WB weight bearing, PCS physical component 
summary, MCS mental component summary
VAS pain scale AOS SF-36
Non-WB WB Pain Disability Total PCS MCS
Preoperative baseline 3.4 4.1 37.2 38.2 37.7 35.1 53.2
Week 24 1.1 2.1 25.9 27.6 26.7 42.9 53.5
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Statistical analysis
Treatment safety and efficacy were assessed by comparing 
the preoperative baseline scores on the primary and second-
ary outcome measures with the scores recorded during fol-
low-up evaluations at 6, 12, and 24 weeks, using Student’s 
t test. Ninety-five per cent confidence intervals were used 
to assess variability using AOS scores and mean area of 
oedema (mm2) via MRI.
Results
Thirty patients with verified OCD were initially assessed 
for inclusion in this pilot study. Of these, 25 patients were 
excluded due to ankle instability or other associated pathol-
ogy, or were from the practice of another surgeon.
Five patients with six OCD lesions of the talus met all 
inclusion and exclusion criteria, and underwent arthro-
scopic debridement followed by arthroscopic filling of 
the defect with rhPDGF-BB/β-TCP matrix. None of these 
patients withdrew from the study before the final follow-up 
visit at 24 weeks; all patients were seen for follow-up at the 
correct intervals and had complete data.
Mean patient age was 52 ± 8.5 years, and mean BMI 
was 26.3 ± 5.0. Three of the patients were female and 
two were male. In one patient, the OCD occurred in the 
left ankle; in the remainder, it occurred in the right ankle. 
One patient had two lesions on the same ankle (one on 
the medial and one on the lateral side of the talus). Defect 
Fig. 1  Average scores on the VAS pain questionnaire, from preopera-
tive baseline (preop) to final follow-up (week 24). A lower score indi-
cates decreased pain
Fig. 2  Average scores on the mental and physical components of 
the SF-36 Health Survey questionnaire, from preoperative base-
line (preop) to final follow-up (week 24). Increased scores indicate 
improvement
Fig. 3  Average scores on the 
total Ankle Osteoarthritis Scale 
(AOS) and on the pain and dis-
ability components, from preop-
erative baseline (preop) to final 
follow-up (week 24). Decreased 
scores indicate improvement
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parameters are summarised in Table 1. Four patients had 
undergone a prior debridement, and three had undergone 
more than one prior debridement. Four lesions were shoul-
der lesions and two were not.
Mean scores for pain and disability at baseline and at 
24 weeks post-operative follow-up (as measured by the 
VAS, SF-36, and AOS scales) are listed in Table 2. Changes 
in these scores are illustrated in Figs. 1, 2 and 3.
No major adverse events related to the graft were 
observed. Over the course of the study, there were no 
wound infections, wound breakdowns, reoperations, loss of 
motion, symptoms of loose body/impingement, or synovi-
tis. (Any additional adverse events affecting the ankle are 
listed by patient in the “Appendix”).
Evaluation of bone marrow oedema as visualised by 
MRI, preoperatively and at 24 weeks post-operatively, is 
shown in Table 3 and Fig. 4 (note that retrograde drilling 
was not possible in this joint, as only minimal cartilage 
remained).
Incorporation of the graft as visualised by CT scan, at 
2- and 24-week follow-ups, is shown in Table 4 and Fig. 5.
Discussion
The most important finding of the present study was that 
a new arthroscopic procedure yielded improved pain and 
functional scores for patients with OCD, and enhanced 
healing of these lesions (as confirmed by MRI and CT 
scans). No short-term complications were observed despite 
close monitoring of the patients. This prospective, single-
centre, case-series-based, proof-of-concept study evaluated 
the initial safety, efficacy, and clinical utility of rhPDGF/β-
TCP as an arthroscopic treatment following debridement 
for OCD of the talus in five patients.
Results at 6-month follow-up indicate that the method is 
both safe and effective, at least initially. Mean non-weight 
Fig. 4  Magnetic resonance imaging (MRI) scans. a Preoperative 
sagittal view showing bone marrow oedema. b Post-operative sagittal 
view showing reduction in the oedema signal. c Preoperative coronal 
view showing bone marrow oedema. d Post-operative coronal view 
showing reduced marrow signal
Table 3  Mean area of oedema (mm2) via MRI
Parameter Preop 24 weeks
Coronal oedema 95 (CI 20–171) 71 (CI 0–208)
Sagittal oedema 140 (CI 50–229) 37 (CI 0–93)
Average 118 (CI 45–190) 54 (CI 0–150)
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bearing VAS pain scores decreased by 68 %, mean weight 
bearing VAS pain scores decreased by 49 % (VAS), and 
mean scores on the AOS disability component decreased by 
28 % (Table 2; Figs. 1, 3). MRI scans confirmed a reduc-
tion in subchondral oedema over time in all patients, with 
the mean area decreasing by 25 % on the coronal view and 
by 74 % on the sagittal view from preoperative baseline to 
final follow-up scans at 24 weeks (Table 3; Fig. 4). No het-
erotopic ossification was evident on follow-up CT scans, 
and the graft was incorporated in all five cases (Table 4; 
Fig. 5). In addition, no major adverse events related to the 
graft were observed, and none of the patients required reop-
eration for their OCD.
With procedures such as OATS, not only is there 
increased risk of knee donor-site morbidity [19], but the 
force of impact during graft insertion can damage both the 
talus and the chondrocytes in the graft [5]. Thus, gentler 
insertion of the non-cellular preparation used in our pro-
cedure confers the added advantage of reduced damage to 
ankle and graft, as well as the knee.
In a large, multi-centre, prospective, randomised, con-
trolled, clinical trial, DiGiovanni et al. [10] compared the 
safety and efficacy of PDGF/β-TCP versus autogenous 
bone grafts (autografts) in patients requiring hindfoot or 
ankle fusion. The study found that the PDGF treatment 
resulted in comparable fusion rates, less pain, and fewer 
side effects compared to treatment with autograft. Due to 
its role as a mitogenic and chemotactic factor for fibro-
blasts [30, 32], osteoblasts [22–24, 26, 29], chondrocytes 
[28, 33], and tenoblasts [9, 27, 35], PDGF also holds con-
siderable promise in restoring bone integrity in lesions such 
as OCDs. Healing and restoration of the subchondral bone 
may thus make our method more effective in the long term 
than cartilage grafts, OATS, or ACI. In addition, this new 
procedure offers an alternative that should prove to be less 
invasive and more economical than either OATS or ACI.
The current study has several strengths. Its prospec-
tive design provides proof of concept in support of the 
original hypothesis. Especially promising was the fact that 
four of the five patients had undergone previous debride-
ments that required revision, but no revisions or additional 
procedures were required following the rhPDGF/β-TCP 
treatment. Limitations included small sample size, a short 
follow-up period, lack of a concurrent control group, and 
potential selection bias due to patient recruitment from 
a single clinical centre. In addition, the improved area of 
marrow oedema observed at final follow-up could be due 
in part to a period of relatively limited mobility. A larger, 
multi-centre, randomised, controlled trial with a minimum 
2-year follow-up period is needed and is planned in order 
to address these limitations.
The clinical relevance of this study is that it demon-
strates that a new technique using a human growth fac-
tor for the treatment of OCD can be safe, well tolerated, 
and clinically useful. If the results of the present study are 
confirmed in a larger trial, the potential benefits include 
lower cost, less post-operative pain, fewer wound compli-
cations, and shorter recovery time due to its less invasive 
nature; no non-unions of osteotomies; considerable reduc-
tions in patient-reported pain several months after surgery; 
and better long-term outcomes, compared with more inva-
sive procedures such as OATS or ACI, which are currently 
the standard of care. In addition, there is no need for grafts 
(and therefore no donor-site morbidity), and this mixture 
of growth factor and osteoconductive matrix may help to 
Table 4  Mean area of OCD lesions and percentage filled by graft, as 
visualised via CT scan
Parameter 2 weeks 24 weeks
Coronal view (mm2) 69 58
Sagittal view (mm2) 89 76
Amount of defect filled by graft (coronal view) (%) 85.2 54
Amount of defect filled by graft (sagittal view) (%) 84.6 61
Fig. 5  Post-operative computed tomography (CT) scans. a Coronal 
view at 2 weeks showing fill of the osteochondral defect. b Coronal 
view at final scan (24 weeks) showing healing of the bone in the base 
of the osteochondral defect and resorption of periarticular tricalcium 
phosphate granules
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stabilise the lesion after debridement, preventing further 
progression.
Conclusion
In conclusion, the use of rhPDGF in an osteoconductive 
matrix shows promise as a clinically useful alternative for 
the treatment of OCD lesions of the talus following arthro-
scopic debridement. An expanded series or randomised, 
controlled trial is required to confirm these results.
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Appendix: adverse events
See Tables 5, 6, and 7.
Table 5  Adverse events as reported by patients
Patient ID Adverse event description Onset date
001 Fell using crutches, stuck splint at study ankle 12 March 2012
Slipped on stairs, muscles sore at ankle 11 May 2012
Development of stress fracture at calcaneus of study foot (osteoporosis-Z-
score-3.7, severely osteoporotic)
Noted during May 2012
Small clot with superficial phlebitis right ankle Noted during 17 May 2012 appointment
Severed ACL right leg (study side) Noted during unscheduled visit 18 July 2012
Fell off bike, landed on right side (knee area) Early August 2012
Occasional catching and locking symptoms study ankle Noted during 24 August 2012 visit
Medial pain, study ankle Noted during 24 August 2012 visit
Dropped 1-lb weight on study ankle Noted during 24 August 2012 visit
002 Right hip replacement 6 March 2013
Continued pain left study ankle. Bony prominence subtalar joint noted during 
May 9 follow-up—patient had injection for this
Noted during unscheduled visit 4 April 2013
003 Cast causing pain—removed and replaced Noted during unscheduled visit 23 October 2012
Sharp, acute pain right study ankle 5 November 2012
Shooting pains medial ankle, decreased sensation throughout entire dorsum of 
foot
Noted during 15 November 2012 visit
Patient notes colour difference right study ankle, swelling in foot, lump on bottom 
of foot (noticed during December 2012), sore big toe with pain radiating to foot, 
numbness
Noted during unscheduled visit 21 December 2012
Severe OA left knee—referred to specialist Referral 27 December 2012
After short walk, sharp pain in ankle 6 January 2013
Corneal surgery for displaced lens 10 January 2013
004 Graft not contained as well as hoped Noted during 7 June 2012 visit
Stiff ankle Noted during 12 July 2012
Ankle becomes swollen after running any distance Noted during 15 November 2012 visit
005 Slipped in elevator, caught himself 24 June 2012
Patient notes occasional numb/tingling sensation Noted during 25 June 2012 visit
Residual material back of joint Noted during 25 June 2012 visit
Dropped brick on ankle 16 August 2012
Withdrawal symptoms from discontinuation of tramadol—insomnia, loss of 
appetite
Noted during 30 August 2012 visit
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